NCT07266259 Effect of Levocarnitine Plus Myoinositol Versus Myoinositol Alone on Hormonal and Insulin Resistance in PCOS Women
| NCT ID | NCT07266259 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mst.Sumyara Khatun |
| Condition | Polycystic Ovary Syndrome (PCOS) |
| Study Type | INTERVENTIONAL |
| Enrollment | 72 participants |
| Start Date | 2025-09-19 |
| Primary Completion | 2026-08-18 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 72 participants in total. It began in 2025-09-19 with a primary completion date of 2026-08-18.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if combination of levocarnitine and myoinositol works better than myoinositol alone on insulin resistance and hormonal parameters in subfertile women with insulin resistant polycystic ovary syndrome . It will also learn about the safety of drug levocarnitine and myoinositol. The main questions it aims to answer are: Does combined action of levocarnitine and myoinositol improve insulin resistance and hormonal parameters in comparison to myoinositol alone in subfertile women with insulin resistant polycystic ovary syndrome ? What medical problems do participants have when taking drug levocarnitine and myoinositol? Researchers will compare the drug combination of levocarnitine and myoinositol to myoinositol alone to see if combination therapy works better? Participants will: Take drug levocarnitine and myoinositol or a myoinositol alone twice daily for 3 months Visit the clinic once after 3 months for checkups and tests Keep a diary of their symptoms and the number of times.
Eligibility Criteria
Inclusion Criteria: * Age:18-40 years old. * Diagnosed cases of PCOS patients(both old \& new cases) according to International evidence-based guideline criteria 2023 * Primary or secondary subfertility. * Insulin resistance (HOMA-IR \>2.6) Exclusion Criteria: * Hypothyroidism * Diabetes mellitus * Hormonal (Myo-inositol,D-chiro-inositol) or insulin sensitizing drugs like Metformin,Pioglitazone etc. treatment in the last three months * Known hypersensitivity to Myo-inositol and Levo-carnitine * Pregnancy
Contact & Investigator
Jemine Banu, MS
STUDY DIRECTOR
Bangladesh Medical University
Frequently Asked Questions
Who can join the NCT07266259 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 40 Years, studying Polycystic Ovary Syndrome (PCOS). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07266259 currently recruiting?
Yes, NCT07266259 is actively recruiting participants. Contact the research team at sumirmc09@gmail.com for enrollment information.
Where is the NCT07266259 trial being conducted?
This trial is being conducted at Dhaka, Bangladesh, Dhaka, Bangladesh.
Who is sponsoring the NCT07266259 clinical trial?
NCT07266259 is sponsored by Mst.Sumyara Khatun. The principal investigator is Jemine Banu, MS at Bangladesh Medical University. The trial plans to enroll 72 participants.